EWTX insider Form 4 shows director purchase at avg $18.64

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. director reports open-market share purchase. A reporting person who serves as a director of Edgewise Therapeutics, Inc. (EWTX) bought 10,700 shares of common stock on 11/11/2025 in an open-market transaction coded as a purchase. The shares were acquired at an average price of $18.6358 per share, with multiple trades executed in a price range from $18.55 to $18.65. Following this transaction, the director beneficially owns 23,702 shares of Edgewise Therapeutics common stock, held directly. The reporting person has indicated a willingness to provide detailed trade-by-trade pricing information upon request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Jonathan C

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2025		P		10,700	A	$18.6358(1)	23,702	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $18.55 to $18.65, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

	/s/ John R. Moore, Attorney-in-Fact for Fox Jonathan C	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Edgewise Therapeutics (EWTX) report on this Form 4?

The filing reports that a director of Edgewise Therapeutics, Inc. (EWTX) purchased 10,700 shares of common stock in an open-market transaction on 11/11/2025, coded as a purchase.

At what price did the Edgewise Therapeutics (EWTX) director buy the shares?

The director acquired the shares at an average price of $18.6358 per share, with individual trades executed at prices ranging from $18.55 to $18.65, inclusive.

How many Edgewise Therapeutics (EWTX) shares does the reporting person own after this transaction?

After the reported purchase, the director beneficially owns 23,702 shares of Edgewise Therapeutics common stock, held in direct ownership.

What is the relationship of the reporting person to Edgewise Therapeutics (EWTX)?

The reporting person is identified as a director of Edgewise Therapeutics, Inc. and filed the report as a single reporting person.

Was the Edgewise Therapeutics (EWTX) Form 4 transaction part of a Rule 10b5-1 trading plan?

The form includes a checkbox related to transactions under a Rule 10b5-1(c) trading plan, but the excerpt does not show that this box was marked as selected.

Does the filing provide details on each individual trade price for the Edgewise Therapeutics (EWTX) shares?

The filing states that the reported price is an average price and notes that the director will provide full information on the number of shares purchased at each separate price within the $18.55 to $18.65 range upon request.